Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Rating) – Investment analysts at William Blair upped their Q2 2022 earnings per share (EPS) estimates for shares of Actinium Pharmaceuticals in a report issued on Monday, May 16th. William Blair analyst A. Hsieh now expects that the biotechnology company will post earnings of $1.28 per share for the quarter, up from their prior estimate of ($0.27). William Blair also issued estimates for Actinium Pharmaceuticals’ Q3 2022 earnings at ($0.29) EPS, Q4 2022 earnings at ($0.41) EPS, FY2022 earnings at $0.35 EPS, Q1 2023 earnings at ($0.32) EPS, Q2 2023 earnings at ($0.34) EPS, Q3 2023 earnings at ($0.36) EPS, Q4 2023 earnings at ($0.39) EPS, FY2023 earnings at ($1.41) EPS and FY2024 earnings at $0.47 EPS.
A number of other equities analysts have also weighed in on ATNM. Zacks Investment Research lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 15th. HC Wainwright reissued a “buy” rating and issued a $45.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 12th.
Several institutional investors have recently bought and sold shares of the company. State Street Corp raised its position in shares of Actinium Pharmaceuticals by 12.5% in the first quarter. State Street Corp now owns 63,015 shares of the biotechnology company’s stock valued at $322,000 after buying an additional 7,023 shares during the last quarter. Blair William & Co. IL lifted its stake in Actinium Pharmaceuticals by 15.8% in the 1st quarter. Blair William & Co. IL now owns 100,566 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 13,700 shares in the last quarter. BlackRock Inc. lifted its stake in Actinium Pharmaceuticals by 1.1% in the 1st quarter. BlackRock Inc. now owns 230,950 shares of the biotechnology company’s stock worth $1,180,000 after purchasing an additional 2,618 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Actinium Pharmaceuticals during the 4th quarter worth approximately $84,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Actinium Pharmaceuticals by 135.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 26,109 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 15,030 shares in the last quarter. Institutional investors and hedge funds own 8.63% of the company’s stock.
About Actinium Pharmaceuticals (Get Rating)
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.
- Get a free copy of the StockNews.com research report on Actinium Pharmaceuticals (ATNM)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.